Novartis Dissolves CAR-T Unit Cutting 120 Positions
Aug 31, 2016, 11:32 AM
by
Michael Croft
Forbes | Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts.
August 31, 2016 | Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts. Forbes